更新于：2024-12-17
Amorolfine Hydrochloride
盐酸阿莫罗芬
更新于：2024-12-17
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1991-12-18), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C21H36ClNO |
InChIKeyXZKWIPVTHGWDCF-KUZYQSSXSA-N |
CAS号78613-38-4 |
关联
16
项与 盐酸阿莫罗芬 相关的临床试验MULTICENTRIC, RANDOMIZED, EVALUATOR BLINDED CLINICAL INVESTIGATION for the EVALUATION of EFFICACY and SAFETY of TWO PRODUCTS for the TREATMENT of ONYCHOMYCOSIS
Q-switched Nd:YAG laser versus Amorolfine Hydrochloride Cream in treatment of Distal lateral subungual onychomycosis in older adults
Pilot Study on the Evaluation of the Efficacy, Tolerability and Safety of Topical and Oral Antifungals in the Treatment of Onychomycosis and Creation of a Library of Dermatological Clinical Isolates
100 项与 盐酸阿莫罗芬 相关的临床结果
登录后查看更多信息
100 项与 盐酸阿莫罗芬 相关的转化医学
登录后查看更多信息
100 项与 盐酸阿莫罗芬 相关的专利（医药）
登录后查看更多信息
285
项与 盐酸阿莫罗芬 相关的文献（医药）2024-12-01FUNDAMENTAL & CLINICAL PHARMACOLOGY
Nociceptive TRP channels function as molecular target for several antifungal drugs
Article
作者: Takahashi, Kenji ; Ohta, Toshio ; Okabe, Shota ; Hashimoto, Miho
Abstract:
Background/objectives:
Topically applied antifungal agents can induce adverse effects, such as pain and irritation. The transient receptor potential (TRP) channels—TRPA1 and TRPV1—mainly expressed in sensory neurons, act as sensors for detecting irritants. This study aims to evaluate the involvement of nociceptive channels in topical antifungal‐induced pain and irritation. We tested nine topical antifungals belonging five classes: isoconazole, econazole, miconazole, clotrimazole, and ketoconazole as imidazoles; liranaftate as a thiocarbamate; terbinafine as an allylamine; amorolfine as a morpholine; and butenafine as a benzylamine.
Methods:
Intracellular calcium concentrations ([Ca2+]i) and membrane currents in response to antifungals were measured to estimate channel activity using heterologously expressing cells and isolated mouse sensory neurons.
Results:
In mouse TRPA1‐expressing cells, all the tested drugs induced an increase in [Ca2+]i, which was abrogated or reduced by a TRPA1 blocker. Although many drugs evoked the TRPA1‐nonspecific [Ca2+]i response at high concentrations, responses to clotrimazole, ketoconazole, and liranaftate were TRPA1 specific and elicited current responses in TRPA1‐expressing cells. In mouse TRPV1‐expressing cells, clotrimazole and ketoconazole elicited [Ca2+]i and current responses. In mouse sensory neurons, liranaftate‐induced increase in [Ca2+]i was abrogated by a TRPA1 blocker and Trpa1 deletion. Responses to ketoconazole were inhibited by TRPA1 and TRPV1 blockers and by the genetic deletion of either channel.
Conclusion:
These results suggest that topical antifungal‐induced pain and irritation are attributable to the activation of nociceptive TRPA1 and/or TRPV1 channel/s. Consequently, caution should be exercised in the use of topical antifungals with symptoms of pain.
2024-09-01MYCOSES
Efficacy of Amorolfine in Onychomycosis Treatment: A Mixed‐Effects Models and Multivariate Logistic Regression Analysis
Article
作者: Jiang, Guan ; Ding, Mingming ; Du, Chichi ; Zhang, Lin
ABSTRACT:
Background:
Onychomycosis (OM) is a common nail infection treated with amorolfine hydrochloride nail lacquer in China. Monitoring drug concentrations and using dermoscopy to evaluate treatment efficacy may provide new insights.
Objective:
The study aims to analyse amorolfine concentrations in nails with mild to moderate OM, assess treatment outcomes using dermoscopy and explore factors influencing drug concentrations and efficacy.
Methods:
Patients with mild to moderate OM confirmed by fungal microscopy were enrolled. Amorolfine nail lacquer was applied twice weekly for 36 weeks. Monthly nail samples measured amorolfine concentrations using liquid chromatography. Dermoscopy was performed before and after treatment to evaluate responses. Mixed‐effects models and logistic regression analysed factors affecting drug concentrations and outcomes.
Results:
Ninety‐seven nails were included. Amorolfine concentrations increased over time, with higher levels in females, fingernails, 2nd–5th digits and superficial white OM (p < 0.05). Age was a risk factor, while drug concentration and OM type were protective for clinical efficacy (p < 0.05). Peak concentration correlated with clinical (r = 0.487, p = 0.000) and mycological (r = 0.433, p = 0.000) responses. Dermoscopic features improved significantly in successful cases (p < 0.05).
Limitations:
In the assessment of fungal efficacy, only fungal microscopy was used, and fungal cultures were not performed. The study was limited by a small sample size and the lack of a longer follow‐up to assess relapse.
Conclusion:
Amorolfine concentrations vary with patient and nail characteristics, influencing efficacy. Dermoscopy is valuable for monitoring OM treatment.
2024-08-01Dermatologie (Heidelberg, Germany)
Review
作者: Schaller, Martin ; Paasch, Uwe ; Mayser, Peter ; Klonowski, Esther ; Nenoff, Pietro ; Uhrlaß, Silke
Topical antifungals with activity against dermatophytes include amorolfine, allylamines, azoles, ciclopiroxolamine, and tolnaftate. Polyene antimycotics, such as amphotericin B and nystatin, alternatively, miconazole are suitable for yeast infections of the skin and mucous membranes. For severe yeast infections of the skin and mucous membranes, oral triazole antimycotics, such as fluconazole and itraconazole, are used. Pityriasis versicolor is treated topically with antimycotics, and in severe forms also orally with itraconazole, alternatively fluconazole. Terbinafine, itraconazole and fluconazole are currently available for the systemic treatment of severe dermatophytoses, tinea capitis and onychomycosis. In addition to proven therapeutic regimens, unapproved (off-label use) intermittent low-dose therapies are increasingly being used, particularly in onychomycosis. Oral antimycotics for the treatment of tinea capitis and onychomycosis in children and adolescents can only be used off-label in Germany. In general, any oral antifungal treatment should always be combined with topical antifungal therapy. In tinea corporis and tinea cruris caused by Trichophyton (T.) mentagrophytes ITS (internal transcribed spacer) genotype VIII (T. indotineae), there is usually terbinafine resistance. Identification of the species and genotype of the dermatophyte and resistance testing are required. The drug of choice for T. mentagrophytes ITS genotype VIII dermatophytoses is itraconazole. In individual cases, treatment-refractory onychomycosis may be due to terbinafine resistance of T. rubrum. Here too, resistance testing and alternative treatment with itraconazole should be considered. Therapy monitoring should be carried out culturally and, if possible, using molecular methods (polymerase chain reaction). Alternative treatment options include laser application, and photodynamic therapy (PDT).
100 项与 盐酸阿莫罗芬 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 传染性皮肤病 | 中国 | 2000-04-10 | |
| 皮肤念珠菌病 | 日本 | 1993-10-01 | |
| 银屑病 | 日本 | 1993-10-01 | |
| 足癣 | 日本 | 1993-10-01 | |
| 白癜风 | 日本 | 1993-10-01 | |
| 真菌病 | 日本 | 1991-12-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 50 | (Loceryl NL+Cosmetic Varnish) | 製夢繭構鬱襯鏇觸鏇廠(積齋餘襯鬱蓋艱築窪鏇) = 夢網築壓鬱積簾構鏇簾 夢網膚鹹顧廠膚壓構膚 (製夢繭淵鑰製顧鏇夢憲, 鹹構遞鹹顧衊遞襯網窪 ~ 鏇衊膚廠觸膚鏇膚鬱製) 更多 | - | 2018-10-09 | ||
(Loceryl NL 12 Weeks) | 製夢繭構鬱襯鏇觸鏇廠(積齋餘襯鬱蓋艱築窪鏇) = 廠鏇艱蓋糧繭築築憲簾 夢網膚鹹顧廠膚壓構膚 (製夢繭淵鑰製顧鏇夢憲, 簾繭範衊衊網顧製範廠 ~ 築鏇觸糧獵鹹窪製觸鹹) 更多 | ||||||
临床4期 | 20 | (Loceryl NL) | 糧廠範壓積憲壓製顧鹹(鏇鑰網襯窪積選膚蓋積) = 願壓網憲製範選構衊鏇 鬱獵觸醖艱鏇願製蓋選 (製構獵膚選範選襯壓餘, 壓鏇鏇壓鹹膚衊積鬱積 ~ 鑰夢繭鏇遞淵夢願夢齋) 更多 | - | 2018-10-03 | ||
(Ciclopirox NL) | 糧廠範壓積憲壓製顧鹹(鏇鑰網襯窪積選膚蓋積) = 簾鏇鹹選餘鏇夢齋夢夢 鬱獵觸醖艱鏇願製蓋選 (製構獵膚選範選襯壓餘, 齋鬱鏇衊觸築鹹製選醖 ~ 憲淵顧顧網繭襯糧鏇鏇) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用